Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Rhea-AI Summary
Aura Biosciences (Nasdaq: AURA) priced a public offering to sell 39,591,000 shares and pre-funded warrants for up to 3,800,000 shares, at $6.00 and $5.99999 respectively, with gross proceeds expected of $260.3 million. Aura granted underwriters a 30-day option for up to 6,508,650 additional shares. The offering is expected to close on or about May 5, 2026. Aura intends to use approximately $205.1 million of net proceeds, plus existing cash, to advance clinical programs and registration-enabling activities for bel-sar, and to repurchase up to 6,922,870 shares from Matrix at $5.64 per share.
Positive
- Gross proceeds expected of $260.3 million
- Approximately $205.1 million earmarked for clinical programs
- Planned repurchase of up to 6,922,870 Matrix-held shares
Negative
- Issuance of 39,591,000 new common shares increases outstanding stock
- Underwriters' option could add 6,508,650 additional shares
- Pre-funded warrants for up to 3,800,000 shares are dilutive upon exercise
News Market Reaction – AURA
In the May 4 session, AURA gained 19.12%, reflecting a significant positive market reaction. Argus tracked a peak move of +43.7% during that session. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.5x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Equity offering priced | Neutral | +5.7% | Pricing of public offering expected to raise $75.0M for clinical programs. |
| May 15 | Equity offering proposed | Neutral | +5.7% | Proposed public offering of common stock and warrants under an existing registration. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior offering announcements saw average 1-day moves of 5.71%, indicating past financings were absorbed constructively.
Recent news for Aura Biosciences has focused on financing, clinical progress, and investor outreach. Prior offering-related announcements in May 2025 raised about $75.0M to fund bel-sar programs in early choroidal melanoma, metastases to the choroid, ocular surface cancers and non-muscle invasive bladder cancer, with average next-day moves of 5.71%. More recently, earnings and conference updates highlighted continued Phase 3 CoMpass enrollment and multiple 2026 data readouts. Today’s larger offering extends that pattern of using equity raises to support pipeline development.
Key Terms
pre-funded warrants financial
underwritten public offering financial
exercise price financial
Rule 462(b) regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of
All of the shares and pre-funded warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be
Aura intends to use
Leerink Partners, TD Cowen and Evercore ISI are acting as joint bookrunning managers for the offering. LifeSci Capital is also acting as a bookrunning manager in the offering. Citizens Capital Markets is acting as a co-manager for the offering.
A shelf registration statement relating to the shares of common stock and pre-funded warrants offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2024 and declared effective by the SEC on April 5, 2024 and a related registration statement that was filed with the SEC on May 4, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended (and became automatically effective upon filing). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on May 4, 2026, and are available on the SEC’s website located at www.sec.gov. A final prospectus supplement containing additional information relating to the offering and an accompanying prospectus will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Aura’s lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA. Aura’s mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
Forward-Looking Statements
Various statements in this release concerning the use of proceeds, timing and completion of the public offering and stock repurchase on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Aura’s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Aura’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering and stock repurchase, as well as those risks more fully discussed in the section entitled “Risk Factors” in the prospectus supplement and registration statement referenced above, Aura’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 30, 2026 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that Aura will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Aura undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
Source: Aura Biosciences, Inc.
